Martin Dahl, PhD, of AnaptysBio discusses the findings and limitations of a study analyzing use of ANB032 in patients with atopic dermatitis (AD). Lawrence Eichenfield, MD, chief of pediatric and ...
AnaptysBio (NASDAQ:ANAB – Get Free Report) had its target price reduced by research analysts at JPMorgan Chase & Co. from $66 ...
The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock, ...
AnaptysBio ANAB has been analyzed by 9 analysts ... for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate ...
Note that ANB032 is already no longer part of that pipeline. Until recently it was, and it was being tried in atopic dermatitis. I will address that right away. On December 11, 2024, AnaptysBio ...
Zacks.com on MSN20d
Biotech Stock Roundup: Updates From GILD, REGN, GSK, ANAB Down on Study Data, EWTX GainsIt was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.
The revision follows AnaptysBio's recent Phase 2b trial failure of ANB032 in atopic dermatitis (AD), which led to its removal from the sum-of-the-parts (SOTP) valuation of the company. The stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback